Showing results (541-550 of 635) with videos related to

Sort By:
Pageof 64
European Journal of Heart Failure|May 22, 2023
Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trialSafia Chatur, Jonathan W Cunningham, Muthiah Vaduganathan, et al.
JACC. Heart Failure|December 6, 2025
Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF TrialFinnian R Mc Causland, Safia Chatur, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|May 16, 2025
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trialMisato Chimura, Mingming Yang, Alasdair D Henderson, et al.
JACC. Heart Failure|June 2, 2026
Ambulatory Stage C2D Heart Failure Definitions and Current Therapeutic Approaches: JACC: Heart Failure Position StatementShannon M Dunlay, Monica Colvin, Jennifer A Cowger, et al.
JACC. Heart Failure|September 28, 2023
Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER TrialAlexander Peikert, Bradley A Bart, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|September 2, 2022
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trialJohn W Ostrominski, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF TrialScott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
The New England Journal of Medicine|April 11, 2014
Spironolactone for heart failure with preserved ejection fractionBertram Pitt, Marc A Pfeffer, Susan F Assmann, et al.
JAMA Cardiology|February 22, 2023
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVERJawad H Butt, Kieran F Docherty, Brian L Claggett, et al.
JACC. Asia|February 19, 2024
Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER TrialXiaowen Wang, Carolyn S P Lam, Muthiah Vaduganathan, et al.
Pageof 64